Paradoxical expression pattern of the epithelial mesenchymal transition-related biomarkers CD44, SLUG, N-cadherin and VSIG1/Glycoprotein A34 in gastrointestinal stromal tumors

AIM To evaluate the immunohistochemical (IHC) expression of five biomarkers, commonly involved in epithelial mesenchymal/mesenchymal epithelial transition (EMT/MET), in gastrointestinal stromal tumors (GISTs). METHODS In 80 consecutive GISTs the IHC examinations were performed using the EMT-related antibodies E-cadherin, N-cadherin, SLUG, V-set and immunoglobulin domain containing 1 (VSIG1) and CD44. RESULTS The positivity rate was 88.75% for SLUG, 83.75% for VSIG1, 36.25% for CD44 and 10% for N-cadherin. No correlation was noted between the examined markers and clinicopathological parameters. Nuclear positivity for SLUG and VSIG1 was observed in all cases with distant metastasis. The extra-gastrointestinal stromal tumors (e-GISTs) expressed nuclear positivity for VSIG1 and SLUG, with infrequent positivity for N-cadherin and CD44. The low overall survival was mainly dependent on VSIG1 negativity (P = 0.01) and nuclear positivity for SLUG and/or CD44. CONCLUSION GIST aggressivity may be induced by nuclear up-regulation of SLUG and loss or cytoplasm-to-nuclear translocation of VSIG1. SLUG and VSIG1 may act as activated nuclear transcription factors. The CD44, but not N-cadherin, might also have an independent prognostic value in these tumors. The role of the EMT/MET-related transcription factors in the evolution of GISTs, should be revisited with a larger dataset. This is the first study exploring the IHC pattern of VSIG1 in GISTs.

[1]  Z. Szentirmay,et al.  PKCθ utility in diagnosing c-KIT/DOG-1 double negative gastrointestinal stromal tumors. , 2017, Oncotarget.

[2]  K. S. Hall,et al.  SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour , 2017, British Journal of Cancer.

[3]  E. Wardelmann,et al.  Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Hua Wu,et al.  The role of CD44 in epithelial–mesenchymal transition and cancer development , 2015, OncoTargets and therapy.

[5]  S. Gurzu,et al.  Epithelial-mesenchymal, mesenchymal-epithelial, and endothelial-mesenchymal transitions in malignant tumors: An update. , 2015, World journal of clinical cases.

[6]  L. Zeng,et al.  Dysregulated expression of Snail and E-cadherin correlates with gastrointestinal stromal tumor metastasis , 2014, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[7]  Guohui Wan,et al.  miR-137 regulates epithelial-mesenchymal transition in gastrointestinal stromal tumor , 2014, Tumor Biology.

[8]  Jing-jing Zhao,et al.  Decreased expression of V‐set and immunoglobulin domain containing 1 (VSIG1) is associated with poor prognosis in primary gastric cancer , 2012, Journal of surgical oncology.

[9]  L. Zeng,et al.  Expression and Significance of Twist, E-Cadherin, and N-Cadherin in Gastrointestinal Stromal Tumors , 2012, Digestive Diseases and Sciences.

[10]  Wenmei Li,et al.  Prognostic significance of PTEN, Ki-67 and CD44s expression patterns in gastrointestinal stromal tumors. , 2012, World journal of gastroenterology.

[11]  Huajian Chen,et al.  [Expression and significance of Slug, E-cadherin and N-cadherin in gastrointestinal stromal tumors]. , 2012, Zhonghua yi xue za zhi.

[12]  James A. Eddy,et al.  Integrated Proteomics and Genomics Analysis Reveals a Novel Mesenchymal to Epithelial Reverting Transition in Leiomyosarcoma through Regulation of Slug* , 2010, Molecular & Cellular Proteomics.

[13]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[14]  H. Joensuu Risk stratification of patients diagnosed with gastrointestinal stromal tumor. , 2008, Human pathology.

[15]  K. Lillemoe,et al.  Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behavior , 2003, Journal of Gastrointestinal Surgery.

[16]  V. Filonenko,et al.  Glycoprotein A34, a novel target for antibody-based cancer immunotherapy. , 2006, Cancer immunity.

[17]  J. Pettitt The cadherin superfamily. , 2005, WormBook : the online review of C. elegans biology.

[18]  M. Zöller,et al.  CD44 in Cancer Progression: Adhesion, Migration and Growth Regulation , 2003, Journal of Molecular Histology.

[19]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[20]  M. Choti,et al.  CD44 Loss in Gastric Stromal Tumors as a Prognostic Marker , 2004, The American journal of surgical pathology.

[21]  D. Mangham,et al.  The normal structure and function of CD44 and its role in neoplasia. , 1998, Molecular pathology : MP.